1. Necroptosis: A new way of dying?
    Britt Hanson, 2016, Cancer Biology & Therapy CrossRef
  2. Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine
    Feng-Ying Zhang et al, 2015, IJMS CrossRef
  3. Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation
    Prahlad V. Raninga et al, 2016, Apoptosis CrossRef
  4. Shikonin induces necroptosis by reactive oxygen species activation in nasopharyngeal carcinoma cell line CNE-2Z
    Zixuan Zhang et al, 2017, J Bioenerg Biomembr CrossRef
  5. Shikonin inhibits inflammation and chondrocyte apoptosis by regulation of the PI3K/Akt signaling pathway in a rat model of osteoarthritis
    Daijie Fu et al, 2016 CrossRef
  6. Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation.
    Bin Lu et al, 2017, Acta Pharmacol Sin CrossRef
  7. Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance
    Sheng-Yen Lin et al, 2017, Autophagy CrossRef
  8. Non-apoptotic Cell Death in Malignant Tumor Cells and Natural Compounds
    Jing Ye et al, 2018, Cancer Letters CrossRef
  9. Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis
    Kelby W. Wegner et al, 2017, Trends in Pharmacological Sciences CrossRef
  10. RIP1 and RIP3 contribute to shikonin-induced glycolysis suppression in glioma cells via increase of intracellular hydrogen peroxide
    Bin Lu et al, 2018, Cancer Letters CrossRef
  11. null
    Francis Ka-Ming Chan et al, 2019 CrossRef
  12. null
    Walter Gottlieb Land, 2018 CrossRef
  13. Bulnesia sarmientoi Supercritical Fluid Extract Exhibits Necroptotic Effects and Anti-Metastatic Activity on Lung Cancer Cells
    Heng-Long Wang et al, 2018, Molecules CrossRef
  14. Inhibition of lung cancer by 2-methoxy-6-acetyl-7-methyljuglone (MAM) through induction of necroptosis by targeting receptor-interacting protein 1 (RIP1)
    Wen Sun et al, 2018, Antioxidants & Redox Signaling CrossRef
  15. Shikonin inhibits cancer cell cycling by targeting Cdc25s
    Shoude Zhang et al, 2019, BMC Cancer CrossRef
  16. Redox biology of regulated cell death in cancer: A focus on necroptosis and ferroptosis.
    Marc Diederich, 0 CrossRef
  17. A new pyridazinone exhibits potent cytotoxicity on human cancer cells via apoptosis and poly-ubiquitinated protein accumulation
    Denisse A. Gutierrez et al, 2019, Cell Biol Toxicol CrossRef
  18. Exploiting Necroptosis for Therapy of Acute Lymphoblastic Leukemia
    Caterina Mezzatesta et al, 2019, Front. Cell Dev. Biol. CrossRef
  19. Shikonin derivatives for cancer prevention and therapy.
    Joelle C Boulos et al, 2019, Cancer Lett CrossRef
  20. Cancer and necroptosis: friend or foe?
    Stephan Philipp et al, 2016, Cell. Mol. Life Sci. CrossRef
  21. RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species.
    Zijian Zhou et al, 0 CrossRef
  22. Enhancement of NK cells proliferation and function by Shikonin.
    Yan Li et al, 2017, Immunopharmacol Immunotoxicol CrossRef
  23. Shikonin alleviates the biotoxicity produced by pneumococcal pneumolysin
    Xiaoran Zhao et al, 2017, Life Sciences CrossRef
  24. Pharmacological properties and derivatives of shikonin-A review in recent years.
    Chuanjie Guo et al, 2019, Pharmacol Res CrossRef
  25. MLKL contributes to shikonin-induced glioma cell necroptosis via promotion of chromatinolysis
    Ye Ding et al, 2019, Cancer Letters CrossRef
  26. Cell death mechanisms in eukaryotes.
    J Grace Nirmala et al, 2020, Cell Biol Toxicol CrossRef
  27. Jujuboside B promotes the death of acute leukemia cell in a RIPK1/RIPK3/MLKL pathway-dependent manner.
    Miao-Miao Jia et al, 2020, Eur J Pharmacol CrossRef
  28. 11-Methoxytabersonine Induces Necroptosis with Autophagy through AMPK/mTOR and JNK Pathways in Human Lung Cancer Cells
    Di Ge et al, 2020, Chem. Pharm. Bull. CrossRef
  29. Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
    Hang Cao et al, 2020, CMC CrossRef
  30. Cell apoptosis, autophagy and necroptosis in osteosarcoma treatment
    Jing Li et al, 2016, Oncotarget CrossRef
  31. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy
    Mao-Bin Meng et al, 2016, Oncotarget CrossRef
  32. The TAT-RasGAP317-326 anti-cancer peptide can kill in a caspase-, apoptosis-, and necroptosis-independent manner
    Mathieu Heulot et al, 2016, Oncotarget CrossRef
  33. Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells
    Qiaoli Zhao et al, 2015, Oncotarget CrossRef
  34. Induction of programmed necrosis: A novel anti-cancer strategy for natural compounds
    Jie Yu et al, 2020, Pharmacology & Therapeutics CrossRef
  35. null
    Jie Yu et al, 2020 CrossRef
  36. Label-Free Classification of Apoptosis, Ferroptosis and Necroptosis Using Digital Holographic Cytometry
    Kendra L. Barker et al, 2020, Applied Sciences CrossRef
  37. Necroptosis: A novel manner of cell death, associated with stroke (Review)
    Chenglin Liu et al, 2017, Int J Mol Med CrossRef
  38. The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications
    Sheng-Kai Hsu et al, 2020, Cancers CrossRef
  39. Shikonin overcomes drug resistance and induces necroptosis by regulating the miR-92a-1-5p/MLKL axis in chronic myeloid leukemia
    Xianbo Huang et al, 2020, Aging CrossRef
  40. Natural product scaffolds as inspiration for the design and synthesis of 20S human proteasome inhibitors
    Grace E. Hubbell et al, 2020, RSC Chem. Biol. CrossRef
  41. Induction of apoptosis by Shikonin through ROS-mediated intrinsic and extrinsic apoptotic pathways in primary effusion lymphoma
    Md Masud Alam et al, 2021, Translational Oncology CrossRef
  42. Natural Products as Inducers of Non-Canonical Cell Death: A Weapon against Cancer
    Giulia Greco et al, 2021, Cancers CrossRef
  43. Caspase-Independent Regulated Necrosis Pathways as Potential Targets in Cancer Management
    Jianyao Lou et al, 2021, Front. Oncol. CrossRef
  44. Targeting Drug Chemo-Resistance in Cancer Using Natural Products.
    Wamidh H Talib et al, 2021, Biomedicines CrossRef
  45. Molecular mechanism of shikonin inhibiting tumor growth and potential application in cancer treatment
    Qiang Wang et al, 2021 CrossRef
  46. Shikonin Inhibits Cell Growth of Sunitinib-Resistant Renal Cell Carcinoma by Activating the Necrosome Complex and Inhibiting the AKT/mTOR Signaling Pathway
    Sascha D. Markowitsch et al, 2022, Cancers CrossRef
  47. Systematic Screening of Chemical Constituents in the Traditional Chinese Medicine Arnebiae Radix by UHPLC-Q-Exactive Orbitrap Mass Spectrometry
    Lian Zhu et al, 2022, Molecules CrossRef
  48. Anti-cancer Research on Arnebiae radix-derived Naphthoquinone in Recent Five Years
    Lian Zhu et al, 2022, PRA CrossRef
  49. Mechanism of Bile Acid-Induced Programmed Cell Death and Drug Discovery against Cancer: A Review
    Jung Yoon Jang et al, 2022, IJMS CrossRef
  50. Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy
    Wenxia Li et al, 2022, Front. Oncol. CrossRef
  51. Necroptosis: A Pathogenic Negotiator in Human Diseases
    Hitesh Singh Chaouhan et al, 2022, IJMS CrossRef
  52. Mode of Actions of Bile Acids in Avoidance of Colorectal Cancer Development; and their Therapeutic Applications in Cancers - A Narrative Review
    Kulvinder Kochar Kaur et al, 2022, J. Pharm. Nutr. Sci. CrossRef
  53. Synthetic Small Molecule Modulators of Hsp70 and Hsp40 Chaperones as Promising Anticancer Agents
    Bianca Nitzsche et al, 2023, IJMS CrossRef
  54. The anti-leukemia activity and mechanisms of shikonin: a mini review
    Han Dong et al, 2023, Front. Pharmacol. CrossRef
  55. Potential applications of ferroptosis inducers and regulatory molecules in hematological malignancy therapy
    Xiao Tang et al, 2023, Critical Reviews in Oncology/Hematology CrossRef
  56. Anoikis and cancer cell differentiation: novel modes of shikonin derivatives anticancer action in vitro
    Dijana Bovan et al, 2024, Mol Biol Rep CrossRef
  57. A Novel Necroptosis-Related Signature Can Predict Prognosis and Chemotherapy Sensitivity in Multiple Myeloma
    Jun-Yao Jiang et al, 2024, Technol Cancer Res Treat CrossRef
  58. Exploring natural killer cell-related biomarkers in multiple myeloma: a novel nature killer cell-related model predicting prognosis and immunotherapy response using single-cell study
    Jing Zhao et al, 2024, Clin Exp Med CrossRef
  59. Enhanced Osteosarcoma Immunotherapy via CaCO3 Nanoparticles: Remodeling Tumor Acidic and Immune Microenvironment for Photodynamic Therapy
    Yinghua Gao et al, 2024, Adv Healthcare Materials CrossRef
  60. Label-free fluorescence lifetime imaging for the assessment of cell viability in living tumor fragments
    Jason T. Smith et al, 2024, J. Biomed. Opt. CrossRef